Karen L. Zaderej Axogen, Inc. (AXGN) insider trading activity

Karen L. Zaderej is CEO of Axogen, Inc.. Currently has a direct ownership of 1.14 Million shares of AXGN, which is worth approximately $15.3 Million. The most recent transaction as insider was on Mar 21, 2024, when has been sold 39,280 shares (Common Stock) at a price of $7.68 per share, resulting in proceeds of $301,670. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.14M

0% 3M change

6.62% 12M change

Total Value Held $15.3 Million

Karen L. Zaderej Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 21 2024	SELL Open market or private sale	$301,670 $7.68 p/Share	39,280 Reduced 3.32%	1,143,788 Common Stock
Mar 16 2024	BUY Exercise of conversion of derivative security	-	110,322 Added 8.77%	1,146,954 Common Stock
Jul 18 2023	BUY Grant, award, or other acquisition	-	22,076 Added 2.02%	1,072,746 Common Stock
Mar 16 2023	BUY Exercise of conversion of derivative security	-	37,975 Added 3.49%	1,050,670 Common Stock
Dec 27 2022	BUY Exercise of conversion of derivative security	-	4,400 Added 0.43%	1,012,695 Common Stock
Dec 15 2022	BUY Exercise of conversion of derivative security	$136,137 $5.09 p/Share	26,746 Added 2.58%	1,008,295 Common Stock
Jul 19 2022	SELL Sale (or disposition) back to the issuer	$76,280 $8.4 p/Share	9,081 Reduced 0.92%	981,549 Common Stock
Jul 18 2022	BUY Grant, award, or other acquisition	-	22,076 Added 2.18%	988,409 Common Stock
Mar 16 2022	BUY Exercise of conversion of derivative security	-	25,950 Added 2.62%	966,333 Common Stock
Feb 15 2022	BUY Grant, award, or other acquisition	-	13,978 Added 1.46%	940,383 Common Stock
Dec 27 2021	SELL Payment of exercise price or tax liability	$17,064 $9.74 p/Share	1,752 Reduced 0.19%	925,677 Common Stock
Dec 27 2021	BUY Exercise of conversion of derivative security	-	4,400 Added 0.47%	927,429 Common Stock
Dec 20 2021	SELL Payment of exercise price or tax liability	$11,485 $9.24 p/Share	1,243 Reduced 0.13%	923,029 Common Stock
Dec 20 2021	BUY Exercise of conversion of derivative security	-	3,125 Added 0.34%	924,272 Common Stock
Nov 24 2021	BUY Exercise of conversion of derivative security	$468,756 $8.95 p/Share	52,375 Added 5.38%	921,147 Common Stock
Aug 13 2021	BUY Exercise of conversion of derivative security	$170,655 $3.67 p/Share	46,500 Added 5.08%	868,772 Common Stock
Aug 12 2021	BUY Exercise of conversion of derivative security	$42,013 $5.09 p/Share	8,254 Added 0.99%	822,272 Common Stock
Aug 10 2021	BUY Exercise of conversion of derivative security	$381,750 $5.09 p/Share	75,000 Added 8.06%	855,018 Common Stock
Aug 06 2021	SELL Open market or private sale	$770,390 $18.79 p/Share	41,000 Reduced 4.8%	814,018 Common Stock
Jul 20 2021	SELL Payment of exercise price or tax liability	$169,190 $19.2 p/Share	8,812 Reduced 1.12%	780,018 Common Stock
Jul 19 2021	BUY Grant, award, or other acquisition	-	22,077 Added 2.72%	788,830 Common Stock
Apr 16 2021	BUY Exercise of conversion of derivative security	$509,000 $5.09 p/Share	100,000 Added 11.55%	765,912 Common Stock
Mar 25 2021	BUY Exercise of conversion of derivative security	$126,615 $3.67 p/Share	34,500 Added 4.93%	665,912 Common Stock
Feb 17 2021	SELL Payment of exercise price or tax liability	$143,805 $18.71 p/Share	7,686 Reduced 1.2%	631,412 Common Stock
Feb 16 2021	BUY Grant, award, or other acquisition	-	29,999 Added 4.51%	634,916 Common Stock

Also insider at

EYPT

EyePoint Pharmaceuticals, Inc. Healthcare

KLZ

Karen L. Zaderej

CEO

Watertown, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AXGN shares.

Notify only if

Value

Insider Trading

Get notified when an Axogen, Inc. insider buys or sells AXGN shares.

Notify only if

Operation

Value

Type

News

Receive news related to Axogen, Inc.

Track Activities on AXGN

Account